NCT00814762View on ClinicalTrials.gov

Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 3, 2009

Primary Completion Date

August 18, 2010

Study Completion Date

August 18, 2010

Conditions
AIDS
Interventions
BIOLOGICAL

HIV Vaccine 732462

Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.

BIOLOGICAL

Placebo vaccine

Two doses of placebo, injected intramuscularly, at an interval of approximately one month

Trial Locations (6)

12157

GSK Investigational Site, Berlin

20099

GSK Investigational Site, Hamburg

20246

GSK Investigational Site, Hamburg

50937

GSK Investigational Site, Cologne

80335

GSK Investigational Site, Munich

91054

GSK Investigational Site, Erlangen

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY